Articles tagged with Insulin
Patients with maturity-onset diabetes of the young (MODY1) benefit from therapies targeting a specific pathway regulating insulin secretion, not oral medications linked to beta-cell destruction. Research suggests MODY1 patients may become dependent on insulin injections sooner due to cellular stress levels.
Scientists have developed novel insulin mimetopes that can induce regulatory T cells to produce tolerance against insulin, halting the development of type 1 diabetes in young mice. In a humanized mouse model, the new vaccine efficiently stimulates regulatory T cells, which can impede the immune system's attack on insulin-producing cells.
Researchers at UNC and NC State create a synthetic patch filled with natural beta cells that can secrete insulin on demand, avoiding rejection risks and hypoglycemia. The 'smart cell patch' demonstrated successful blood sugar regulation in small animal models of type-1 diabetes.
A study of 5,644 women found that diabetes treatment decreases mammographic density, while insulin use increases it. The researchers also urge women with and without diabetes to adopt simple lifestyle changes to reduce breast cancer risk.
Researchers at the University of Utah are developing a 'smart' insulin that can automatically lower blood sugar levels after consumption. The grant-funded project aims to create an insulin that deactivates when blood glucose drops below a certain level, reducing the risk of serious health threats associated with improper dosing.
A UC Riverside-led study links thirdhand smoke exposure to insulin resistance and hyperglycemia in mice, a precursor to type 2 diabetes. Exposure to toxins from second-hand smoke causes oxidative stress, damaging proteins and DNA, leading to insulin resistance.
A multinational trial found that injecting a new long-acting insulin with another drug, IDegLira, improved glucose control in Type 2 diabetes patients. Participants on the combination product lost weight and experienced fewer episodes of hypoglycemia compared to those receiving basal insulin alone.
A study found that degludec/liraglutide was associated with greater HbA1c level reduction, weight loss, and lower hypoglycemia rates compared to glargine. The medication also had more nonserious gastrointestinal adverse events.
A study found that subcutaneous insulin infusion does not prevent oxidative stress and inflammation in the liver, despite reducing glycemic variability. The therapy also failed to preserve balance of anti- and pro-oxidant species.
Scientists at the University of Michigan have developed a novel method to observe insulin production in the pancreas of living animals. The technique allows researchers to see how much insulin is present and respond to sugar levels in real-time, revealing surprising insights into pancreatic function.
Researchers developed a new approach to designing insulin-based pharmaceuticals using self-assembling nano-insulin. This method could lead to more personalized medications with fewer side effects for Type 1 Diabetes patients.
Researchers have designed a material that can encapsulate human islet cells before transplanting them, allowing patients to control their blood sugar levels without immunosuppressant drugs. In tests on mice, encapsulated human cells cured diabetes for up to six months.
The article discusses the development and future promise of Continuous Glucose Monitoring (CGM) technology, which combines CGM with an insulin pump and sophisticated algorithms for automating insulin control. Key challenges facing successful commercialization include cost, reimbursement issues, and lack of FDA approval for insulin dosing.
Researchers are conducting one of the largest-ever long-term clinical trials of an artificial pancreas system to regulate blood sugar levels in individuals with type 1 diabetes. The trial aims to test the safety and efficacy of the system, which uses advanced algorithms and sensors to mimic a healthy person's glucose regulating function.
Researchers have developed a novel microencapsulation method using seaweed-derived hydrogel to protect pancreatic islets from ice damage during transplantation. The technique facilitates real-time cell viability assessments and reduces the need for cryoprotectants, promoting a more effective and safer treatment approach.
Researchers found that soaking islet cells in Anti-aging Glycopeptide (AAGP) protects them from tacrolimus, a toxic drug commonly used during transplants. This allows for fewer cells to be used, potentially treating more patients with the Edmonton Protocol.
Researchers at Université de Genève found that cold exposure alters microbiota composition, leading to increased brown fat activation, improved insulin sensitivity, and weight loss. The discovery highlights the key role of Akkermansia muciniphila in regulating nutrient absorption and may lead to new anti-obesity treatments.
A pilot study has demonstrated that a mechanical artificial pancreas can better maintain normal blood glucose levels than multiple daily insulin injections in patients with pancreatitis. The treatment combines an AI-powered pump with islet cell transplantation, enabling the transplanted cells to survive longer and produce more insulin.
Researchers at UC Santa Barbara have developed an insulin pill using novel drug delivery technology that shows early promise as a form of diabetes therapy. The pill's oral delivery system could circumvent the discomfort associated with injections, leading to improved patient compliance and potentially more effective treatment.
A large-scale analysis of three diabetes registries found that insulin pump use is associated with lower mean HbA1c levels and better blood sugar control in children and adolescents with type 1 diabetes. Pump use was also more common among certain subgroups, such as girls and non-minority ethnic groups.
A new study by the University of Colorado shows that sleep deprivation can lead to impaired insulin sensitivity. The longer people are awake during their biological night, the worse their sensitivity to insulin becomes, according to the study's findings.
Researchers found that insulin resistance is associated with a significantly worse prognosis for metastatic breast cancer patients. Lifestyle changes, such as diet and exercise, may help improve outcomes. Insulin targeting therapies could also be beneficial.
Researchers found that insulin stimulates the release of dopamine in the brain, leading to a feeling of pleasure. The study also suggests that people may choose high-carb or low-fat meals based on their insulin levels, potentially affecting weight and type II diabetes.
Researchers have developed an intestinal patch device containing insulin that can be swallowed as a capsule, demonstrating efficacy in managing blood glucose levels in diabetic rats. The patches showed excellent mucoadhesive strength and released insulin within five hours, reducing blood glucose levels significantly.
A pharmacy-led glycemic control program is linked to improved outcomes for surgical patients with diabetes, including fewer complications and readmissions. Patients in the program had better blood sugar control, reduced hospital readmissions, and lower medical costs.
A recent study found that patients with better insulin-producing cells before weight loss surgery are more likely to eliminate diabetes. The research suggests that measuring insulin cells' performance can help doctors predict which patients will benefit from the procedure, emphasizing the importance of early procedures.
A pilot study found early insulin therapy to be as effective as 15 months of oral therapy, improving A1C levels from 10.1% to 6.7% in insulin-treated group and 9.9% to 6.8% in oral therapy group, with no severe hypoglycemia reported
A post-hoc analysis of the ACCORD study found that higher doses of insulin were not associated with increased cardiovascular death. The study's findings provide reassurance for physicians and patients with diabetes, but underscore the need for further research to clarify the potential risks of insulin use.
Researchers at Duke University Medical Center and the University of Alberta have discovered a new biochemical pathway that controls insulin secretion from islet beta cells in the pancreas. The study found that impairing this pathway, known as S-AMP production, disrupts normal glucose-stimulated insulin secretion.
A/Prof Shane Grey's team aims to make significant improvements in islet transplantation therapy, making it a clinically realistic option for more individuals with type 1 diabetes. They focus on calming the immune response of patients to islet transplantation, which could lead to treated individuals living drug-free in the long term.
Researchers at UMMS have discovered a new pathway that triggers regeneration of beta cells in the pancreas. This innovative approach may aid in the development of diabetes treatments by increasing the number of insulin-producing cells in response to increased demand.
A study by University of Alberta researchers discovered a new molecular pathway that manages insulin production, offering hope for restoring the 'dimmer switch' in Type 2 diabetes. The findings suggest that this pathway can be revived to control insulin secretion from islet cells.
Researchers at Karolinska Institutet have discovered a mechanism that explains how insulin-producing cells can be both insulin-resistant and insulin-sensitive at the same time. The study identifies a key factor, PI3K-C2α, that causes a switch in signaling pathways, leading to beta cell proliferation.
Researchers found that brief intervals of exercise during sedentary periods can lower children's blood glucose and insulin levels, and may protect against diabetes, cardiovascular disease, and cancer. The study suggests that even short activity breaks can help overcome negative effects on the body.
Researchers found altered mitochondrial DNA in pre-diabetic individuals with insulin resistance, who had lower amounts of mitochondrial DNA and higher methylation levels. This discovery may help prevent Type II diabetes by identifying a biomarker for early intervention.
Babies diagnosed with diabetes are now immediately tested for all 22 genetic causes, reducing referral time from over four years to under two months. This early comprehensive gene testing provides accurate information on clinical features that haven't yet developed, enabling doctors to anticipate and prevent medical problems.
A recent NIH study found that restricting dietary fat led to a 68% higher rate of body fat loss compared to cutting the same number of carbohydrate calories. The researchers discovered that fat restriction resulted in a greater imbalance between consumed and burned fat, leading to more significant weight loss.
A study published in the British Medical Journal found that insulin pump users had a substantially lower risk of dying from cardiovascular disease than those using multiple daily injections. The researchers believe more frequent monitoring and training may be key to the therapy's benefits.
Researchers discovered insulin delivered via nasal cavity reaches affected brain areas, improving memory in a mouse model. The study suggests potential future treatments using gastrointestinal hormones like insulin to combat Alzheimer's disease.
A new study reveals that skipping breakfast triggers major blood sugar spikes and impairs insulin responses in type-2 diabetics throughout the day. The researchers found that fasting until noon causes extraordinary glucose peaks after lunch and dinner, highlighting the importance of not skipping meals for diabetics.
A gene mutation called ankyrin-B has been found to cause cells to absorb glucose faster, leading to fat storage and type 2 diabetes. The mutations are common among certain populations, including African Americans and Caucasians, and may provide a genetic link to modern diet-related diseases.
Researchers have created an implantable device that continuously measures blood sugar levels and automatically releases insulin as needed, eliminating the need for constant monitoring and daily injections. The artificial pancreas maintained blood glucose within target range nearly 80% of the time in computer simulations.
Researchers at Scripps Research Institute are accelerating development of anti-diabetic compounds, focusing on peroxisome proliferator-activated receptors gamma (PPARG) and overcoming glitazone safety concerns. The new grant aims to inform clinical development and assess effects on bone.
Researchers have created a smart insulin patch that can detect increases in blood sugar levels and secrete doses of insulin, potentially replacing painful injections for diabetes. The patch uses microneedles to administer insulin, which is released when blood glucose levels get too high.
Researchers have discovered a potential target for the treatment of type 2 diabetes by inhibiting the S6K1 protein, which increases insulin sensitivity in mice. In animal models, S6K1 deficient mice displayed improved insulin response and reduced risk of developing diabetes.
Alternative drug-delivery systems are being explored to overcome syringe injection drawbacks, including ointments, dissolvable tablets and micro-needle skin patches. Several promising results have been shown in animal testing, but widespread adoption will require changing the mindset of pharmaceutical companies and regulators.
The study identified urocortin 3 as a key player in regulating insulin production and blood sugar levels. By understanding how this hormone interacts with other cells and systems, researchers hope to develop new treatments for diabetes.
A Montréal research team found that the dual-hormone artificial pancreas provides the most benefits by reducing time spent in nocturnal hypoglycaemia. The study also showed that no participant using the system experienced a nocturnal hypoglycaemia event requiring treatment.
Researchers have identified a gene that may help reactivate insulin-producing beta cells in diabetics. The team, led by Professor Tessem and including four students with Type 1 diabetes, has made significant breakthroughs in understanding the molecular pathways involved.
Diabetes research has made significant progress over the past 50 years, transforming treatment options and patient lives. The development of human insulin, improved glucose testing methods, and advanced delivery systems have greatly enhanced management of the condition.
A new study by Ohio State University researchers suggests that skipping meals can lead to insulin resistance and increased abdominal fat gain in mice. Mice on restricted diets who fasted for extended periods developed metabolic issues, including inflammation and plumper fat cells, compared to those who ate regularly.
In a study published in ETH Zurich, researchers discovered that the microRNA-200 family triggers the death of beta cells, leading to type 2 diabetes. By blocking miR-200 production, scientists can guarantee the survival of these vital cells. This finding has significant implications for the development of new treatments for diabetes.
Researchers found that larger spheres, at least 1.5 millimeters in diameter, triggered lower immune response and developed less scar tissue on their surface. This breakthrough could lead to a viable cure for type 1 diabetes by eliminating the need for lifelong immunosuppressive drugs.
Per capita health care spending for children with diabetes rose 4.1% in 2013, nearly double the 2012 increase, due to higher spending on branded insulin. Out-of-pocket costs for those with diabetes were more than double that of those without the disease.
Five teenagers with Type 1 diabetes will participate in a four-day study to test an 'artificial pancreas,' which automatically monitors and adjusts insulin delivery. The device has the potential to transform diabetes treatment by providing continuous glucose control, reducing anxiety for patients and parents.
Researchers found that eating more protein at breakfast lowered post-meal glucose levels and prompted cells to increase insulin concentrations at the second meal. Consuming 25-30 grams of protein at breakfast may be beneficial for individuals with type 2 diabetes, according to Jill Kanaley.
A pilot study found that daily oral insulin administration induced an immune response without hypoglycemia, supporting the need for a phase 3 trial to prevent islet autoimmunity and diabetes. The study enrolled genetically at-risk children and showed varying responses to different doses of oral insulin.
Researchers found that children given daily doses of oral insulin developed a protective immune response to the disease, which could lead to the development of a vaccine against type 1 diabetes. The study showed increased immunity with higher doses of oral insulin, suggesting a potential treatment strategy.
Researchers have successfully completed the first step in developing an insulin vaccine to prevent type 1 diabetes. The Pre-POINT study showed a positive immune response in children at high risk for the disease, with no adverse reactions observed.
Researchers at UC Davis may have discovered a new way to regenerate beta cells in the pancreas, which could potentially lead to a cure for juvenile diabetes. The study's findings suggest that immature beta cells can arise from alpha cells, offering a new paradigm shift in the treatment of the disease.